Vir Biotechnology, Inc.
VIRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and. Valued at $1.89B, VIR is a small-cap name in its sector. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
Market Cap
$1.89B
Beta
1.63
P/E (TTM)
—
P/E (Fwd)
-4.50
EPS (TTM)
$-1.77
EPS (Fwd)
$-2.49
ROE
-26.1%
ROA
-14.5%
Cash
$532.7M
Total Debt
$93.3M
Free CF
-$38.9M
52W Change
121.9%
Annual Financials
Cash vs Debt
Where VIR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VIR finished 23.92% above its 150-day moving average ($9.28) and 34.82% above its 200-day moving average ($8.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VIR overbought or oversold?
At the September 3, 2026 close, VIR's RSI(14) was 75.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $532.7M in cash comfortably exceeding the $93.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$38.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -26.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $1.58B to $66.5M.
With a beta above 1.5, VIR tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, VIR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Vir Biotechnology, Inc.'s trajectory.